Next Article in Journal
Coumarins, Xanthones and Related Compounds
Previous Article in Journal
Investigation of the Pyridinium Ylide—Alkyne Cycloaddition as a Fluorogenic Coupling Reaction
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 21
Issue 3
10.3390/molecules21030340
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Design, Synthesis and Antibacterial Evaluation of Some New 2-Phenyl-quinoline-4-carboxylic Acid Derivatives

by
Xiaoqin Wang
1,*,
Xiaoyang Xie
1,
Yuanhong Cai
1,
Xiaolan Yang
2,
Jiayu Li
1,
Yinghan Li
1,
Wenna Chen
1 and
Minghua He
1,*
1
School of Pharmacy, Guangdong Medical University, Dongguan 523808, China
2
Department of Hematology, Donghua Affiliated Hospital of Sun Yat-sen University, Dongguan 523110, China
*
Authors to whom correspondence should be addressed.
Molecules 2016, 21(3), 340; https://doi.org/10.3390/molecules21030340
Submission received: 24 January 2016 / Revised: 19 February 2016 / Accepted: 7 March 2016 / Published: 10 March 2016
(This article belongs to the Section Medicinal Chemistry)
Browse Figures
Versions Notes

Abstract

:
A series of new 2-phenyl-quinoline-4-carboxylic acid derivatives was synthesized starting from aniline, 2-nitrobenzaldehyde, pyruvic acid followed by Doebner reaction, amidation, reduction, acylation and amination. All of the newly-synthesized compounds were characterized by 1H-NMR, 13C-NMR and HRMS. The antibacterial activities of these compounds against Gram-negative (Escherichia coli, Pseudomonas aeruginosa) and Gram-positive bacteria (Staphylococcus aureus, Bacillus subtilis), as well as one strain of methicillin-resistant Staphylococcus aureus (MRSA) bacteria were evaluated by the agar diffusion method (zone of inhibition) and a broth dilution method (minimum inhibitory concentration (MIC)), and their structure-activity relationships were obtained and discussed. The results revealed that some compounds displayed good antibacterial activity against Staphylococcus aureus, and Compounds 5a4 and 5a7 showed the best inhibition with an MIC value of 64 μg/mL against Staphylococcus aureus and with an MIC value of 128 μg/mL against Escherichia coli, respectively. The results of the MTT assay illustrated the low cytotoxicity of Compound 5a4.

1. Introduction

Bacterial infection is one of the most complex global health issues of this century [1]. Furthermore, many drug-resistant pathogens have emerged in recent years because of the increasing use or abuse of antibacterial agents [2,3], and antibiotic drug resistance has become a growing problem across the globe in recent years [4]. Currently, many advances for combating antimicrobial resistance have been achieved, such as modifications/improvements of existing antibiotic classes, some anti-adhesion agents against Gram-positive pathogens [5] and efflux pump inhibitors (EPIs) [6]. However, this problem has not been completely resolved. Therefore, the development of novel and effective chemotherapeutics is still in demand to overcome these problems [7,8].
The quinoline ring occurs in various natural products and represents a key motif in medicinal chemistry [9,10,11,12], and its derivatives, quinoline-4-carboxylic acids, are a group of compounds associated with different biological activities, such asantiviral [13], anti-inflammatory [14], antimicrobial [15], anti-atherothrombosis [16], antiemetic [17], anxiolytic [18], antimalarial and antileishmanial [19]. Although quinoline-4-carboxylic acid derivatives exhibit various bioactivities, the research of new quinoline-4-carboxylic acid-based antibacterial drugs has developed slowly. Some quinoline-4-carboxylic acid derivatives exhibited certain antibacterial activity [20,21]. Furthermore, a literature review revealed that the presence of an aryl ring at the second position of quinoline-4-carboxylic acid derivatives exhibits good antibacterial activity for the target compound and plays a significant role in the development of new antibacterials (Figure 1) [6,15,22,23,24,25,26,27], and they are very suitable for further modifications to obtain more effective antibacterial agents. In addition, the structure-activity relationship (SAR) studies of quinolones have indicated that the introduction of a basic group in the quinoline is useful for regulating the physicochemical property and influencing their potency, spectrum and safety [28,29]. All of these stimulated us with great interest to focus on further structural modification of quinoline-4-carboxylic acid in order to find novel derivatives with potential activity against bacterial strains.
Keeping in view the wide range of pharmaceutical activities of quinoline-4-carboxylic acid, in this report, we introduced two amino substituents in the molecule, which may severe as new hydrogen bond donors and receptors to increase binding affinity to the enzyme and also improve their physicochemical properties. Thus, a series of 2-(2’-substutited)-phenyl-quinoline-4-carboxylic acid derivatives was designed, synthesized and evaluated for antibacterial activities.

2. Results and Discussion

2.1. Chemistry

The synthetic pathway for the target Compounds 5a1–5a7 and 5b1–5b6 is depicted in Scheme 1. The intermediate 2-(2-nitrophenyl)-quinoline-4-carboxylic acid (1) is considered to be a category of versatile intermediates that provide building blocks in the synthesis of poly-substituted quinoline-4-carboxylic acid derivatives. Several methods have been developed to date for the synthesis of 2-(2-nitrophenyl)-quinoline-4-carboxylic acid, and these include the Doebner reaction using aniline, 2-nitrobenzaldehyde, pyruvic acid and a catalytic amount of trifluoroacetic acid in ethanol media [14,15], as well as the versatile Pfitzinger reaction by reacting isatin with α-methyl ketone in aqueous ethanol [22,30,31]. 2-(2-nitrophenyl)-quinoline-4-carboxylic acid was also prepared via Doebner reaction under microwave [25,26,32,33]. We opted for the Doebner reaction and explored the influence of two catalysts on the reaction. Treatment of aniline, 2-nitrobenzaldehyde, pyruvic acid and a catalytic amount of trifluoroacetic acid in ethanol media with refluxing for 12 h afforded only a few products, and the pure product must be obtained by flash column chromatography. However, the replacement of trifluoroacetic acid with acetic acid and excessive acetic acid as the solvent instead of ethanol favored the reaction. After completion of the reaction, the mixture was poured into ice water, and the crude product was purified by acid-alkali neutralization and further by recrystallization without flash column chromatography with a total yield of 68%.
The reaction of intermediate 1 with SOCl2 under reflux furnished the product acyl chloride. Subsequently, the treatment of intermediate acyl chloride with 3-(dimethylamino)-1-propylamine in the presence of triethylamine gave Compound 2. In order to obtain the amine functionality, the conventional method for the reduction of the nitro group was attempted by using 80% hydrazine hydrate in the presence of 10% Pd/C and isopropanol as a solvent under reflux, which furnished amino-substituted Compound 3 in a 92% yield [34]. The advantage of this reaction was that product isolation could be facilitated without purification using chromatography. Reaction of amine 3 with acyl chloride and potassium carbonate in dichloromethane gave Compounds 4a and 4b. Because of their poor solubilities, the crude product directly was used in the next reaction without purification. Finally, the target Compounds 5a1–5a7 and 5b1–5b6 were obtained through the reaction of Compounds 4a and 4b with different primary and secondary amines under reflux conditions for 10 h, respectively.
The structures of the target compounds were validated by using 1H-NMR, 13C-NMR and HRMS, and their purities were determined to be above 95% by using HPLC.

2.2. Evaluation of Antibacterial Activity

Firstly, the newly-synthesized Compounds 5a1–5a7, 5b1–5b6 were screened for their in vitro antibacterial activities by the agar diffusion method against a variety of different strains [35,36,37], including Staphylococcus aureus (S. aureus), Bacillus subtilis (B. subtilis), Escherichia coli (E. coli), Pseudomonas aeruginosa (P. aeruginosa) and one strain of methicillin-resistant Staphylococcus aureus (MRSA) bacteria. Their activities were compared to that of Compound 1 and the known antibacterial agents ampicillin and gentamycin. The results are presented in Table 1.
The antibacterial primary screening results revealed that most of the tested compounds showed moderate inhibition against various tested bacterial strains compared to the standard drug. However, most of them exhibited better activity than Compound 1 against the above-mentioned bacteria; this indicated that the structural modifications of 2-phenyl-quinoline-4-carboxylic acid increased the antibacterial activity. Among the synthesized compounds, Compound 5a4 showed significant antibacterial activity against S. aureus and B. subtilis; Compound 5a7 was the most active antibacterial activity against E. coli; and Compound 5b4 exhibited moderate antibacterial activity against MRSA, but all compounds showed weak inhibition action against P. aeruginosa. The LogP values of all of the compounds were predicted on the basis of a computational study using ACDLabs/ChemSketch software. Among the active compounds against all of the mentioned bacteria, it can be clearly seen that the compound (5a4, LogP = 2.26; 5a7, LogP = 1.94; 5b4, LogP = 2.32) with higher lipophilicity displayed higher activity.
Furthermore, with the same basic terminus, Compounds 5a1–5a7 with longer side chains (n = 2, with three bonds between the basic N terminus and carbonyl group) showed stronger antibacterial activity than Compounds 5b1–5b6 with shorter side chains (n = 1, with two bonds between the basic N terminus and carbonyl group) against the above-mentioned bacterial strains, respectively. These indicated that the length of the amide side chain at the ortho-position of the 2-phenyl group had a significant effect on antibacterial activity. On the other hand, alterations of the basic terminus of the amide side chains at the ortho-position of the 2-phenyl group led to varying effects on antibacterial activity. Compounds 5a4, 5a3, 5a2 and 5b4 showed better antibacterial activity than Compounds 5a6, 5a7 and 5b6 against S. aureus and B. subtilis, indicating that rigid cyclic amino group at 2-phenyl is suitable for the anti-Gram-positive bacteria activity. On the contrary, for E. coli, Compounds 5a6, 5a7 and 5b6 exhibited stronger activity than the compounds with rigid cyclic amino substituents(5a2, 5a3, 5a4, 5b4), suggesting that the flexible chain amino group at 2-phenyl can enhance antibacterial activity against E. coli. All of these results demonstrated the importance of the length and flexibility of the amide side chain for antibacterial activity.
In order to further determinate the antibacterial effect of the compounds, the minimum inhibitory concentration (MIC) values against the above-mentioned bacteria strains were measured by a broth dilution method [38,39,40]. The MIC value is a measure to test the antibacterial activity of a compound and is defined as the lowest concentration of antibacterial agent that inhibits visible growth. Ampicillin and gentamycin were used as positive controls in the assay. The MIC values are summarized in Table 2.
The results of MIC values correspond to that obtained by the agar diffusion method as a whole. Some compounds displayed good antibacterial activity against S. aureus, and Compound 5a4 showed the best inhibition against S. aureus with a MIC of 64 μg/mL, which is better than Compound 1. A few compounds exhibited moderate activity against E. coli, and Compound 5a7 had the best activity against E. coli with a MIC of 128 μg/mL. However, all the compounds exhibited weak activity against B. subtilis, P. aeruginosa and MRSA; their MICs were more than 256 μg/mL. Unfortunately, all of these compounds exhibited less potent activity than the standard ones against the above-mentioned strains.

2.3. MTT-Based Cytotoxicity Studies

The in vitro cytotoxicity of Compounds 5a4 and 5a7, which showed the best antibacterial activity, were further examined in mouse macrophage cell lines (RAW 264.7) using the MTT colorimetric assay [40,41]. As shown in Table 3, Compounds 5a4 and 5a7 showed weak cytotoxicity in the RAW 264.7 cells with IC50 values of 98.2 μg/mL and 56.8 μg/mL, respectively, which are similar to the cytotoxicities of ampicillin and gentamycin. The low cytotoxicities for mouse macrophage cells of Compounds 5a4 and 5a7 exhibited their good safety profiles, which indicate that they could be further developed as antibacterial agents for infectious diseases against S. aureus and E. coil, respectively.

3. Experimental Section

3.1. General

All reagents and solvents were of analytical grade and used without further purification. All reactions were monitored by TLC on 0.2 mm-thick silica gel GF254 pre-coated plates. All flash column chromatography were performed with silica gel (200–300 mesh) purchased from Qingdao Haiyang Chemical Co. Ltd., Qingdao, China); 1H-NMR and 13C-NMR spectra were recorded using TMS as the internal standard in CDCl3 or DMSO-d6 with a Bruker BioSpin GmbH spectrometer (Bruker BioSpin, Switzerland) at 400 MHz and 101 MHz, respectively; high resolution mass spectra (HRMS) were recorded on the Shimadzu LCMS-IT-TOF spectrometer (Shimadzu, Tokyo, Japan); the purity of the synthesized compounds was confirmed to be higher than 95% through analytical HPLC (Shimadzu, Tokyo, Japan) performed with a dual pump Shimadzu LC-20AB system (Shimadzu, Tokyo, Japan) equipped with an Ultimate XB-C18 column (4.6 × 250 mm, 5 μm) (Welch, New York, NY USA) and eluted with methanol/water (40:60–70:30) containing 0.1% TFA at a flow rate of 0.5 mL/min.

3.2. Chemistry

3.2.1. Preparation of 2-(2-Nitrophenyl)quinoline-4-carboxylic Acid (1)

Method A: An equimolar mixture of aniline (1.9 g, 20 mmol) and 2-nitrobenzaldehyde (3.0 g, 20 mmol) in ethanol (30 mL) was refluxed for 1 h; pyruvic acid (2.6 g, 30 mmol) and trifluoroacetic acid (0.1 mL) were then added to the reaction mass and further refluxed for 12 h. Reaction completion was monitored by using TLC. The reaction mixture was poured into ice water (60 mL) slowly with vigorous stirring. The solid product was filtered and was added to the aqueous K2CO3; the solution was adjusted to basic, then filtered. The filtrate was acidified with diluted HCl to pH 1–2, and the mixture was extracted with three 40-mL portions of CH2Cl2, The combined organic phase was washed with 40 mL water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by using flash column chromatography to give Compound 1 in a 23% yield.
Method B: A mixture of 2-nitrobenzaldehyde (3.0 g, 20 mmol) and pyruvic acid (3.5 g, 39.8 mmol) was stirred for 15 min; the solid was dissolved. Then, 30 mL acetic acid were added, and the mixture was stirred at 100 °C for 30 min. After aniline (3.7 g, 40 mmol) was added, the mixture was refluxed for 8 h. Then, the reaction mixture was cooled to room temperature and poured into ice water (60 mL); then, aqueous NaOH was added to make the solution basic. The mixture was extracted with three 40-mL portions of CH2Cl2; the water phase was acidified with diluted HCl to pH 1–2, and the precipitated crude product was filtered. A white solid was obtained in a yield of 68% after recrystallization in ethanol. 1H-NMR (400 MHz, DMSO-d6): δ 14.09 (s, 1H), 8.72 (d, J = 8.5 Hz, 1H), 8.19 (s, 1H), 8.09 (d, J = 7.9 Hz, 1H), 8.03 (d, J = 8.2 Hz, 1H), 7.96 (d, J = 7.3 Hz, 1H), 7.88 (t, J = 7.5 Hz, 2H), 7.78 (t, J = 7.6 Hz, 2H).

3.2.2. Preparation of N-(3-(Dimethylamino)propyl)-2-(2-nitrophenyl)quinoline-4-carboxamide (2)

A mixture of Compound 1 (1.2 g, 4.1 mmol) and SOCl2 (15 mL) was stirred under reflux for 3 h. After completion of the reaction, the excess of SOCl2 was distilled off. The obtained yellow residue was added dropwise to the mixture of N,N-dimethylpropylamine (0.5 g, 4.9 mmol), triethylamine(1.6 mL) in CH2Cl2 (30 mL) at 0 °C, then stirred at room temperature for 10 h. The precipitated solid was collected through filtration; the crude product was purified by using flash column chromatography with CH2Cl2 elution to afford Compound 2 as a pale yellow liquid in an 86% yield. 1H-NMR (400 MHz, CDCl3): δ 8.43 (s, 1H), 8.32 (d, J = 8.4 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.75 (t, J = 8.2 Hz, 1H), 7.69 (d, J = 4.0 Hz, 2H), 7.62–7.55 (m, 3H), 3.58 (q, J = 4.0 Hz, 2H), 2.50 (t, J = 6.1 Hz, 2H), 2.20 (s, 6H), 1.84–1.75 (m, 2H).

3.2.3. Preparation of 2-(2-Aminophenyl)-N-(3-(dimethylamino)propyl)quinoline-4-carboxamide (3)

The mixture of Compound 2 (1.0 g, 2.6 mmol), 80% hydrazine hydrate (1.5 mL) in the presence of 10% Pd/C (0.3 g) and isopropanol (25 mL) was heated under reflux for 2 h, and TLC analysis indicated reaction completion; Pd/C was removed by filtration. After concentration in vacuo, 25 mL water were added to the residue; the precipitate was filtered off; the crude product 3 was directly used in the next reaction without purification.

3.2.4. General Preparation of Compounds 4a–4b (GP1)

A solution of the appropriate acid halide (3.9 mmol) in CH2Cl2 (10 mL) was slowly added to a well-stirred mixture of Compound 3 (0.9 g, 2.6 mmol) and anhydrous potassium carbonate (0.6 g, 4.0 mmol) in CH2Cl2 (25 mL) at 0 °C. After completing the addition, the reaction was allowed to warm up to room temperature and then stirred overnight. After concentration in vacuo, 30 mL water were added to the residue; the precipitate formed was filtered off. Because of the poor solubility of Compound 4, the crude product was directly used in the next reaction without purification.

3.2.5. General Preparation of Compounds 5a–5b (GP2)

Appropriate amine (2.0 mL) was added to a stirred refluxing suspension of the chloride Compound 4 (0.5 mmol) in MeOH (25 mL). The mixture was stirred under reflux for 10 h, then cooled to room temperature. After concentration in vacuo, 50 mL water were added to the residue. The mixture was extracted with three 30-mL portions of CH2Cl2. The combined organic phase was washed with 40 mL water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by using flash column chromatography to afford Compounds 5a–5b.
N-(3-(Dimethylamino)propyl)-2-(2-(3-(4-methylpiperazin-1-yl)propanamido)phenyl)quinoline-4-carboxamide (5a1)
Compound 4a was reacted with N-methyl piperazine according to GP2 to give the desired product 5a1. After column chromatography with CH2Cl2/MeOH/Et3N (50:1:0.1) elution, a white solid was obtained in a 64% yield. mp. 182.3–184.2 °C. 1H-NMR (400 MHz, CDCl3): δ 12.40 (s, 1H), 8.53 (d, J = 8.3 Hz, 1H), 8.38 (t, J = 8.0 Hz, 2H), 8.10 (d, J = 8.4 Hz, 1H), 7.92 (s, 1H), 7.81 (t, J = 9.2 Hz, 2H), 7.64 (t, J = 8.0 Hz, 1H), 7.46 (t, J = 7.9 Hz, 1H), 7.23 (t, J = 8.0 Hz, 1H), 3.69 (q, J = 4.0 Hz, 2H), 2.81 (t, J = 7.0 Hz, 2H), 2.64 (t, J = 7.1 Hz, 2H), 2.59–2.54 (m, 2H), 2.47 (s, 4H), 2.24 (d, J = 5.4 Hz, 6H), 2.19 (s, 3H), 2.07 (s, 4H), 1.91–1.84 (m, 2H). 13C-NMR (101 MHz, CDCl3): δ 170.41, 166.76, 157.68, 146.99, 143.79, 137.86, 130.66, 130.62, 129.34, 128.83, 127.69, 125.83, 125.67, 123.69, 123.16, 122.47, 118.60, 59.06, 54.79 (2C), 53.94, 52.66 (2C), 45.75, 45.31 (2C), 40.53, 35.65, 25.23. Purity: 99.4% by HPLC. HRMS (ESI): Calcd. for [M + H]+ (C29H39N6O2) requires m/z 503.3129, found 503.3106.
N-(3-(Dimethylamino)propyl)-2-(2-(3-(pyrrolidin-1-yl)propanamido)phenyl)quinoline-4-carboxamide (5a2)
Compound 4a was reacted with pyrrolidine according to GP2 to give the desired product 5a2. After column chromatography with CH2Cl2/MeOH/Et3N (100:1:0.1) elution, a yellow solid was obtained in a 65% yield. mp. 176.7–178.1 °C. 1H-NMR (400 MHz, CDCl3): δ 12.57 (s, 1H), 8.56 (d, J = 8.3 Hz, 1H), 8.41 (s, 1H), 8.35 (d, J = 8.4 Hz, 1H), 8.11 (d, J = 8.4 Hz, 1H), 7.89 (s, 1H), 7.82–7.74 (m, 2H), 7.62 (t, J = 7.6 Hz, 1H), 7.43 (t, J = 7.8 Hz, 1H), 7.19 (t, J = 7.6 Hz, 1H), 3.67 (dd, J = 11.4, 5.8 Hz, 2H), 2.90 (t, J = 7.3 Hz, 2H), 2.69 (t, J = 7.3 Hz, 2H), 2.54–2.48 (m, 6H), 2.19 (s, 6H), 1.87–1.80 (m, 2H), 1.66 (s, 4H). 13C-NMR (101 MHz, CDCl3): δ 170.29, 166.79, 157.62, 146.92, 143.79, 138.03, 130.67, 130.60, 129.23, 128.93, 127.68, 125.77, 125.58, 123.55, 123.08, 122.25, 118.45, 59.16, 53.92 (2C), 51.84, 45.40 (2C), 40.64, 37.50, 25.33, 23.36 (2C). Purity: 98.8% by HPLC. HRMS (ESI): Calcd. for [M + H]+ (C28H36N5O2) requires m/z 474.2864, found 474.2837.
N-(3-(Dimethylamino)propyl)-2-(2-(3-(diethylamino)propanamido)phenyl)quinoline-4-carboxamide (5a3)
Compound 4a was reacted with diethylamine according to GP2 to give the desired product 5a3. After column chromatography with CH2Cl2/MeOH/Et3N (100:1:0.1) elution, a pale yellow solid was obtained in a 59% yield. mp. 177.2–178.4 °C. 1H-NMR (400 MHz, CDCl3): δ 12.60 (s, 1H), 8.56 (d, J = 8.3 Hz, 1H), 8.41 (s, 1H), 8.35 (d, J = 8.4 Hz, 1H), 8.10 (d, J = 8.4 Hz, 1H), 7.91 (s, 1H), 7.79 (t, J = 7.7 Hz, 2H), 7.62 (t, J = 7.7 Hz, 1H), 7.44 (t, J = 7.8 Hz, 1H), 7.19 (t, J = 7.6 Hz, 1H), 3.67 (q, J = 5.4 Hz, 2H), 2.93 (t, J = 7.2 Hz, 2H), 2.63 (t, J = 7.2 Hz, 2H), 2.58–2.50 (m, 6H), 2.20 (s, 6H), 1.87–1.80 (m, 2H), 0.97 (t, J = 7.1 Hz, 6H). 13C-NMR (101 MHz, CDCl3): δ 170.62, 166.85, 157.54, 146.76, 143.71, 138.07, 130.59 (2C), 129.21, 128.79, 127.63, 125.57, 125.28, 123.50, 123.05, 122.12, 118.42, 58.87, 48.66, 46.71 (2C), 45.31 (2C), 40.33, 35.93, 25.45, 11.36 (2C). Purity: 99.7% by HPLC. HRMS (ESI): Calcd. for [M + H]+ (C28H38N5O2) requires m/z 476.3020, found 476.2994.
N-(3-(Dimethylamino)propyl)-2-(2-(3-(piperidin-1-yl)propanamido)phenyl)quinoline-4-carboxamide (5a4)
Compound 4a was reacted with piperidine according to GP2 to give the desired product 5a4. After column chromatography with CH2Cl2/MeOH/Et3N (100:1:0.1) elution, a yellow solid was obtained in a 60% yield. mp. 168.9–170.1 °C. 1H-NMR (400 MHz, CDCl3): δ 12.52 (s, 1H), 8.51 (d, J = 8.3 Hz, 1H), 8.41–8.30 (m, 2H), 8.12 (d, J = 8.5 Hz, 1H), 7.90 (s, 1H), 7.83–7.75 (m, 2H), 7.63(t, J = 8.0 Hz, 1H), 7.44 (t, J = 7.8 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 3.67 (q, J = 5.6 Hz, 2H), 2.78 (t, J = 7.1 Hz, 2H), 2.67 (t, J = 7.1 Hz, 2H), 2.51 (t, J = 6.0 Hz, 2H), 2.39 (s, 4H), 2.20 (s, 6H), 1.87–1.80 (m, 2H), 1.47–1.39 (m, 4H), 1.36–1.32 (m, 2H). 13C-NMR (101 MHz, CDCl3): δ 170.56, 166.86, 157.58, 146.94, 143.72, 137.88, 130.62, 130.57, 129.30, 128.94, 127.66, 125.85, 125.56, 123.69, 123.08, 122.45, 118.53, 58.92, 54.58, 54.15 (2C), 45.32 (2C), 40.40, 35.45, 25.52 (2C), 25.40, 24.01. Purity: 99.2% by HPLC. HRMS (ESI): Calcd. for [M + H]+ (C29H38N5O2) requires m/z 488.3020, found 488.2995.
N-(3-(Dimethylamino)propyl)-2-(2-(3-morpholinopropanamido)phenyl)quinoline-4-carboxamide (5a5)
Compound 4a was reacted with morpholine according to GP2 to give the desired product 5a5. After column chromatography with CH2Cl2/MeOH/Et3N (90:1:0.1) elution, a pale yellow solid was obtained in a 59% yield. mp. 188.1–189.4 °C. 1H-NMR (400 MHz, CDCl3): δ 12.45 (s, 1H), 8.51 (d, J = 8.6 Hz, 1H), 8.45 (s, 1H), 8.37 (d, J = 8.0 Hz, 1H), 8.10–8.05 (m, 2H), 7.97 (d, J = 12.0 Hz, 1H), 7.81 (t, J = 8.0 Hz, 1H), 7.64 (t, J = 8.0 Hz, 1H), 7.45 (t, J = 8.0 Hz, 1H), 3.73–3.69 (m, 2H), 3.52 (s, 4H), 2.98 (s, 2H), 2.81 (s, 2H), 2.67–2.61 (m, 8H), 2.43 (s, 4H), 2.15–2.12 (m, 2H). 13C-NMR (101 MHz, CDCl3): δ 170.54, 166.83, 157.65, 146.93, 143.75, 137.95, 130.63, 130.59, 129.29, 128.88, 127.66, 125.80, 125.57, 123.66, 123.08, 122.43, 118.49, 66.83 (2C), 58.97, 53.65, 52.79 (2C), 45.40 (2C), 40.29, 35.70, 25.38. Purity: 97.6% by HPLC. HRMS (ESI): Calcd. for [M + H]+ (C28H36N5O3) requires m/z 490.2813, found 490.2785.
N-(3-(Dimethylamino)propyl)-2-(2-(3-((3-(dimethylamino)propyl)amino)propanamido)phenyl)quinoline-4-carboxamide (5a6)
Compound 4a was reacted with 3-dimethyl aminopropyl amine according to GP2 to give the desired product 5a6. After column chromatography with CH2Cl2/MeOH/Et3N (85:2:0.1) elution, a brown solid was obtained in a 55% yield. mp. 171.5–173.4 °C. 1H-NMR (400 MHz, CDCl3): δ12.97 (s, 1H), 8.59 (d, J = 8.2 Hz, 1H), 8.47 (s, 1H), 8.33 (d, J = 8.4 Hz, 1H), 8.12 (d, J = 8.4 Hz, 1H), 7.96 (s, 1H), 7.88–7.79 (m, 2H), 7.63 (t, J = 7.8 Hz, 1H), 7.46 (t, J = 7.8 Hz, 1H), 7.23 (t, J = 7.8 Hz, 1H), 3.72–3.65 (m, 2H), 3.64 (s, 1H), 3.11 (t, J = 5.5 Hz, 2H), 2.97–2.84 (m, 4H), 2.54 (t, J = 6.1 Hz, 2H), 2.43 (t, J = 6.3 Hz, 2H), 2.25 (s, 6H), 2.22 (s, 6H), 1.90–1.84 (m, 2H), 1.78–1.70 (m, 2H). 13C-NMR (101 MHz, CDCl3): δ 171.51, 167.96, 158.57, 147.83, 145.03, 139.21, 131.80, 131.74, 130.31, 129.90, 128.77, 126.66, 126.07, 124.60, 124.14, 123.01, 119.45, 58.93, 49.66, 48.35, 46.52 (2C), 45.77 (2C), 45.42, 41.57, 38.77, 26.60, 25.89. Purity: 98.8% by HPLC. HRMS (ESI): Calcd. for [M + H]+ (C29H41N6O2) requires m/z 505.3286, found 505.3164.
N-(3-(Dimethylamino)propyl)-2-(2-(3-((3-(diethylamino)propyl)amino)propanamido)phenyl)quinoline-4-carboxamide (5a7)
Compound 4a was reacted with 3-diethyl aminopropyl amine according to GP2 to give the desired product 5a7. After column chromatography with CH2Cl2/MeOH/Et3N (85:2:0.1) elution, brown oil was obtained in a 54% yield. 1H-NMR (400 MHz, CDCl3): δ 12.82 (s, 1H), 8.61 (d, J = 8.4 Hz, 1H), 8.45 (s, 1H), 8.35 (d, J = 8.4 Hz, 1H), 8.12 (d, J = 8.4 Hz, 1H), 7.93 (s, 1H), 7.81 (t, J = 7.6 Hz, 2H), 7.63 (t, J = 7.6 Hz, 1H), 7.46 (t, J = 7.8 Hz, 1H), 7.22 (t, J = 8.4 Hz, 1H), 3.68 (q, J = 5.6 Hz, 2H), 3.03 (t, J = 5.9 Hz, 2H), 2.78 (t, J = 4.0 Hz, 2H), 2.70 (t, J = 4.0 Hz, 2H), 2.55–2.44 (m, 8H), 2.19 (s, 6H), 1.88–1.82 (m, 2H), 1.67–1.58 (m, 2H), 1.00 (t, J = 7.0 Hz, 6H). 13C-NMR (101 MHz, CDCl3): δ 170.41, 166.86, 157.47, 146.73, 143.93, 138.11, 130.70, 130.64, 129.21, 128.80, 127.67, 125.56, 124.97, 123.50, 123.04, 121.91, 118.35, 59.00, 51.05, 48.56, 46.63 (2C), 45.42 (2C), 45.32, 40.47, 37.67, 26.18, 25.50, 11.30 (2C). Purity: 98.4% by HPLC. HRMS (ESI): Calcd. for [M + H]+ (C31H45N6O2) requires m/z 533.3599, found 533.3568.
N-(3-(Dimethylamino)propyl)-2-(2-(2-(4-methylpiperazin-1-yl)acetamido)phenyl)quinoline-4-carboxamide (5b1)
Compound 4b was reacted with N-methyl piperazine according to GP2 to give the desired product 5b1. After column chromatography with CH2Cl2/MeOH/Et3N (50:1:0.1) elution, a yellow solid was obtained in a 67% yield. mp. 185.5–186.8 °C. 1HNMR (400 MHz, CDCl3): δ 11.74 (s, 1H), 8.55 (d, J = 12.0 Hz, 1H), 8.48 (t, J = 4.0 Hz, 1H), 8.41 (d, J = 8.3 Hz, 1H), 8.27 (d, J = 8.4 Hz, 1H), 7.85- 7.73 (m, 2H), 7.66–7.57 (m, 2H), 7.43 (d, J = 7.4 Hz, 1H), 7.19 (t, J = 6.5 Hz, 1H), 3.68–3.62 (m, 2H), 3.11 (s, 2H), 2.50 (t, J = 4.0 Hz, 2H), 2.42 (s, 4H), 2.20 (s, 7H), 1.98 (s, 6H), 1.87–1.79 (m, 2H). 13C-NMR (101 MHz, CDCl3): δ 169.28, 166.87, 157.53, 147.50, 143.71, 136.42, 130.36, 130.12(2C), 129.75, 128.08, 127.66, 125.66, 123.91, 123.30, 122.46, 119.06, 63.30, 58.74, 53.84 (2C), 53.25 (2C), 45.58, 45.26 (2C), 40.21, 25.35. Purity: 96.9% by HPLC. HRMS (ESI): Calcd. for [M + H]+ (C28H37N6O2) requires m/z 489.2973, found 489.3036.
N-(3-(Dimethylamino)propyl)-2-(2-(2-(pyrrolidin-1-yl)acetamido)phenyl)quinoline-4-carboxamide (5b2)
Compound 4b was reacted with pyrrolidine according to GP2 to give the desired product 5b2. After column chromatography with CH2Cl2/MeOH/Et3N (100:1:0.1) elution, a yellow solid was obtained in a 66% yield. mp. 180.1–180.9 °C. 1H-NMR (400 MHz, CDCl3): δ 12.32 (s,1H), 8.60 (d, J = 8.3 Hz, 1H), 8.38 (t, J = 8.4 Hz, 2H), 8.20 (d, J = 8.4 Hz, 1H), 7.82 (s, 1H), 7.76 (t, J = 8.4 Hz, 1H), 7.66 (d, J = 7.8 Hz, 1H), 7.61 (t, J = 8.4 Hz, 1H), 7.44 (t, J = 8.4 Hz, 1H), 7.20 (t, J = 8.4 Hz, 1H), 3.70–3.62 (m, 2H), 3.27 (s, 2H), 2.53–2.45 (m, 6H), 2.21 (s, 6H), 1.87–1.79 (m, 2H), 1.51 (s, 4H). 13C-NMR (101 MHz, CDCl3): δ 170.27, 166.92, 157.40, 147.35, 143.62, 137.01, 130.18, 129.92, 129.49, 129.41, 127.53, 127.38, 125.42, 123.65, 123.00, 122.51, 118.67, 61.47, 58.98, 54.50 (2C), 45.35 (2C), 40.43, 25.41, 23.84 (2C). Purity: 97.0% by HPLC. HRMS (ESI): Calcd. for [M + H]+ (C27H34N5O2) requires m/z 460.2707, found 460.2682.
N-(3-(Dimethylamino)propyl)-2-(2-(2-(diethylamino)acetamido)phenyl)quinoline-4-carboxamide (5b3)
Compound 4b was reacted with diethylamine according to GP2 to give the desired product 5b3. After column chromatography with CH2Cl2/MeOH/Et3N (100:1:0.1) elution, a yellow solid was obtained in a 63% yield. mp. 175.4–176.8 °C. 1H-NMR (400 MHz, CDCl3): δ 12.24 (s, 1H), 8.59 (d, J = 8.3 Hz, 1H), 8.45–8.35 (m, 2H), 8.19 (d, J = 8.4 Hz, 1H), 7.80(s, 1H), 7.78 (t, J = 7.8 Hz, 1H), 7.67–7.58 (m, 2H), 7.46 (t, J = 7.8 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 3.66 (q, J = 4.0 Hz, 2H), 3.13 (s, 2H), 2.54–2.44 (m, 6H), 2.19 (s, 6H), 1.86–1.80 (m, 2H), 0.78 (t, J = 8.0 Hz, 6H). 13C-NMR (101 MHz, CDCl3): δ 170.34, 166.96, 157.43, 147.38, 143.66, 137.00, 130.24, 129.97, 129.55, 129.44, 127.58, 127.44, 125.46, 123.72, 123.02, 122.56, 118.72, 61.48, 59.06, 54.54 (2C), 45.40 (2C), 40.53, 25.35, 23.86 (2C). Purity: 98.2% by HPLC. HRMS (ESI): Calcd. for [M + H]+ (C27H36N5O2) requires m/z 462.2865, found 462.2750.
N-(3-(Dimethylamino)propyl)-2-(2-(2-(piperidin-1-yl)acetamido)phenyl)quinoline-4-carboxamide (5b4)
Compound 4b was reacted with piperidine according to GP2 to give the desired product 5b4. After column chromatography with CH2Cl2/MeOH/Et3N (100:1:0.1) elution, a yellow solid was obtained in a 65% yield. mp. 173.2–174.3 °C. 1H-NMR (400 MHz, CDCl3): δ 11.79 (s, 1H), 8.56 (d, J = 8.3 Hz, 1H), 8.39 (d, J = 8.4 Hz, 2H), 8.30 (d, J = 8.4 Hz, 1H), 7.81–7.76 (m, 2H), 7.63 (t, J = 8.4 Hz, 2H), 7.45 (t, J = 8.0 Hz, 1H), 7.20 (t, J = 7.5 Hz, 1H), 3.67 (t, J = 8.0 Hz, 2H), 3.07 (s, 2H), 2.52 (t, J = 8.0 Hz, 2H), 2.34 (s, 4H), 2.20 (s, 6H), 1.88–1.80 (m, 2H), 1.21 (s, 6H). 13C-NMR (101 MHz, CDCl3): δ 169.65, 166.88, 157.45, 147.41, 143.74, 136.91, 130.36, 130.17, 129.94, 129.86, 127.87, 127.24, 125.58, 123.86, 123.23, 122.55, 119.00, 61.69, 59.10, 54.58 (2C), 45.39 (2C), 40.63, 25.48, 23.87 (2C), 23.26. Purity: 98.9% by HPLC. HRMS (ESI): Calcd. for [M + H]+ (C28H36N5O2) requires m/z 474.2864, found 474.2839.
N-(3-(Dimethylamino)propyl)-2-(2-(2-morpholinoacetamido)phenyl)quinoline-4-carboxamide (5b5)
Compound 4b was reacted with morpholine according to GP2 to give the desired product 5b5. After column chromatography with CH2Cl2/MeOH/Et3N (90:1:0.1) elution, a white solid was obtained in a 68% yield. mp. 171.3–172.7 °C. 1H-NMR (400 MHz, CDCl3): δ 11.91 (s, 1H), 8.54 (d, J = 8.3 Hz, 1H), 8.44 (s, 1H), 8.37 (d, J = 8.4 Hz, 1H), 8.25 (d, J = 8.4 Hz, 1H), 7.83–7.76 (m, 2H), 7.66–7.59 (m, 2H), 7.44 (t, J = 7.8 Hz, 1H), 7.20 (t, J = 7.5 Hz, 1H), 3.65 (q, J = 5.4 Hz, 2H), 3.34 (d, J = 3.9 Hz, 4H), 3.12 (s, 2H), 2.49 (t, J = 6.0 Hz, 2H), 2.44–2.37 (m, 4H), 2.19 (s, 6H), 1.87–1.80 (m, 2H). 13C-NMR (101 MHz, CDCl3): δ 168.82, 166.77, 157.55, 147.36, 143.82, 136.55, 130.31, 130.21, 129.68, 129.61, 127.77, 127.37, 125.66, 123.96, 123.17, 122.58, 118.96, 66.08 (2C), 63.98, 58.96, 53.70 (2C), 45.30 (2C), 40.47, 25.29. Purity: 96.6% by HPLC. HRMS (ESI): Calcd. for [M + H]+ (C27H34N5O3) requires m/z 476.2656, found 476.2995.
N-(3-(Dimethylamino)propyl)-2-(2-(2-((3-(dimethylamino)propyl)amino)acetamido)phenyl)quinoline-4-carboxamide (5b6)
Compound 4b was reacted with 3-dimethyl aminopropyl amine according to GP2 to give the desired product 5b6. After column chromatography with CH2Cl2/MeOH/Et3N (85:2:0.1) elution, yellow oil was obtained in a 56% yield. 1H-NMR (400 MHz, CDCl3): δ 12.55 (s, 1H), 8.62 (d, J = 7.8 Hz, 1H), 8.50 (s, 1H), 8.34 (d, J = 8.7 Hz, 1H), 8.21 (d, J = 9.1 Hz, 1H), 7.87 (s, 1H), 7.83–7.78 (m, 1H), 7.75 (d, J = 7.9 Hz, 1H), 7.63 (t, J = 6.9 Hz, 1H), 7.47 (t, J = 7.9 Hz, 1H), 7.24 (t, J = 8.0 Hz, 1H), 3.68 (d, J = 4.4 Hz, 2H), 3.47 (d, J = 2.3 Hz, 2H), 2.60 (d, J = 4.0 Hz, 4H), 2.28–2. 22 (m, 8H), 2.19 (d, J = 2.1 Hz, 6H), 1.90 (t, J = 4.0 Hz, 2H), 1.48–1.41 (m, 2H). 13C-NMR (101 MHz, CDCl3): δ 170.19, 166.93, 157.48, 147.45, 143.67, 136.68, 130.28, 130.10, 129.75, 129.42, 127.66, 127.40, 125.60, 123.91, 123.09, 122.52, 118.73, 60.87, 59.26, 58.94, 46.50, 45.95 (2C), 45.30 (2C), 40.38, 25.63, 25.26. Purity: 95.6% by HPLC. HRMS (ESI): Calcd. for [M + H]+ (C28H39N6O2) requires m/z 491.3135, found 491.3217.

3.3. Antibacterial Studies

3.3.1. Screening for Antibacterial Activity by the Agar Diffusion Method

The in vitro antibacterial activities of newly-synthesized Compounds 5a1–5a7 and 5b1–5b6 were evaluated for their antibacterial activities against S. aureus (ATCC29213), B. subtilis (ATCC6633), E. coli (ATCC25922), P. aeruginosa (ATCC9027) and MRSA (ATCC43300) bacterial strains by the agar diffusion method [36]. Fifteen to twenty milliliters of agar media were poured into each petri dish. Agar-containing plates were dried by placing in a laminar air flow at 37.2 °C for 1 h.
One hundred milliliters of 0.5 McFarland standard of bacterial suspension were inoculated on the agar media and spread on the whole surface with a sterile cotton bud. Using a sterile cork borer, 5-mm wells were made on the seeded agar plates, and 50 mL of test compound at different concentrations (50 and 100 μg/mL) were transferred in to the wells. The plates were prepared in triplicate for each compound. A control was also prepared for the plates in the same way using solvent DMSO. The plates were maintained at 37 ± 2 °C for 24 h. Activities were determined by measuring the diameter of inhibition zone (mm). Ampicillin and gentamycin were used as the standards.

3.3.2. Minimum Inhibitory Concentration Determination

The MIC values were measured by the broth dilution method [40,41]. Five hundred microliters of a stock solution (10.24 mg/mL) of each tested compound in dimethyl sulfoxide (DMSO) were prepared and then diluted with Mueller-Hinton broth to 1024 μg/mL. The strains were grown briefly at 37 °C in Mueller-Hinton media. After 5 h of bacterial growth, the bacterial culture was diluted to obtain a concentration of 5 × 105 cells/mL. Then, 150 μL bacterial suspension were added to each well of the flat-bottomed 96-well tissue culture plate. Two-fold serial dilutions were carried out from the fist well to the tenth well; the final concentrations of the compounds ranged from 1–512 μg/mL; and excess media (150 μL) were discarded from the last well. The plates were incubated at 37 °C for 24 h in an electro-heating standing temperature cultivator and were read visually. The MIC of the sample showing no turbidity was recorded as the lowest concentration of compound that inhibited bacterial growth completely. Each assay was run in triplicate.

3.3.3. Cytotoxicity Assay

The active Compounds 5a4 and 5a7 were further examined for cytotoxicity in mouse macrophage cell lines (RAW 264.7) [41]. The cells were cultured in DMEM medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 100 units/mL penicillin/streptomycin. Cell cultures were maintained in a humidified atmosphere of 5% CO2 at 37 °C. Cells were passaged at pre-confluent densities using a solution containing 0.25% trypsin and 0.5 mM EDTA. Cells were seeded at 1 × 104 cell/well in a 96-well plate for 12 h with 10% FBS, 1% penicillin and streptomycin and 1% l-glutamine, resulting in 80% confluency. Each dose was prepared in 1% FBS medium by 1000× dilution of the drug, which was prepared in DMSO solution to ensure a DMSO concentration less than 0.1%. After 72 h of exposure, the viability was assessed on the basis of cellular conversion of MTT into a formazan product with DMSO for 45 min. The amount of formazan was measured using a microculture plate reader with a test wavelength of 570 nm. Results were expressed as the mean ± SD of three independent experiments.
1H-NMR, 13C-NMR, HRMS and HPLC spectra of the target compounds are shown in the Supplementary Materials.

4. Conclusions

In summary, thirteen novel 2-phenyl-quinoline-4-carboxylic acid derivatives were synthesized using aniline, 2-nitrobenzaldehyde and pyruvic acid as starting materials. The structures of the new compounds were elucidated by using 1H-NMR, 13C-NMR and HRMS, and their purities were determined to be above 95% by using HPLC. The newly-synthesized compounds were investigated for their in vitro antibacterial activities by the agar diffusion method and a broth dilution method. The results of antibacterial evaluation suggested that some compounds displayed moderate antibacterial activity against S. aureus, and Compound 5a4 showed the best inhibition against S. aureus with a MIC of 64 μg/mL. A few compounds exhibited weak activity against E. coli, and Compound 5a7 had the best activity against E. coli with a MIC of 128 μg/mL. The cytotoxic assay exhibited that the active Compound 5a4 showed weak cytotoxicity. These findings indicate the potential usefulness of 5a4 in drug development. Moreover, some structure-activity relationships of 2-phenyl-quinoline-4-carboxylic acid derivatives were determined. The length and flexibility of the amide side chain at the ortho-position of the 2-phenyl group had a significant effect on antibacterial activity. The compound with longer side chains showed stronger activity than the compound with shorter side chains. Moreover, rigid cyclic amino group at 2-phenyl is suitable for the antibacterial activity against S. aureus and B. subtilis, and the introduction of flexible chain amino group at 2-phenyl can enhance antibacterial activity against E. coli. All of these results will be useful in the future to guide the design and modification of new candidate 2-phenyl-quinoline-4-carboxylic acid analogues as antibacterial agents.

Supplementary Materials

Supplementary data (1H-NMR, 13C-NMR, HRMS and HPLC spectra) associated with this article are available at: https://www.mdpi.com/1420-3049/21/3/340/s1.

Acknowledgments

The authors thank the Science and Technology Program of Dongguan (2012108102045), the Science and Technology Development Program of Dongguan (2013108101059) and the Natural Science Foundation of China (21502025) for financial support of this research.

Author Contributions

X.W. and M.H. conceived of and designed the experiments. X.W., X.X., Y.C., X.Y. and J.L. performed the experiments. X.W., Y.L. and W.C. analyzed the data. X.W. wrote the paper. All authors read and approved the final manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Monaghan, R.L.; Barrett, J.F. Antibacterial drug discovery-Then, now and the genomics future. Biochem. Pharmacol. 2006, 71, 901–909. [Google Scholar] [CrossRef] [PubMed]
  2. Shang, R.F.; Liu, Y.; Xin, Z.J.; Guo, W.Z.; Guo, Z.T.; Hao, B.C.; Liang, J.P. Synthesis and antibacterial evaluation of novel pleuromutilin derivatives. Eur. J. Med. Chem. 2013, 63, 231–238. [Google Scholar] [CrossRef] [PubMed]
  3. Khalaj, A.; Nakhjiri, M.; Negahbani, A.S.; Samadizadeh, M.; Firoozpour, L.; Rajabalian, S.; Samadi, N.; Faramarzi, M.A.; Adibpour, N.; Shafiee, A.; et al. Discovery of a novel nitroimidazolyl-oxazolidinone hybrid with potent anti Gram-positive activity: Synthesis and antibacterial evaluation. Eur. J. Med. Chem. 2011, 46, 65–70. [Google Scholar] [CrossRef] [PubMed]
  4. Nathan, C.; Cars, O. Antibiotic Resistance-Problems, Progress, and Prospects. N. Engl. J. Med. 2014, 371, 1761–1763. [Google Scholar] [CrossRef] [PubMed]
  5. Cascioferro, S.; Cusimano, M.G.; Schillaci, D. Antiadhesion agents against Gram-positive pathogens. Future Microbiol. 2014, 9, 1209–1220. [Google Scholar] [CrossRef] [PubMed]
  6. Sabatini, S.; Gosetto, F.; Iraci, N.; Barreca, M.L.; Massari, S.; Sancineto, L.; Manfroni, G.; Tabarrini, O.; Dimovska, M.; Kaatz, G.W.; et al. Re-evolution of the 2‑phenyl-quinolines: Ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance. J. Med. Chem. 2013, 56, 4975–4989. [Google Scholar] [CrossRef] [PubMed]
  7. Livermore, D.M. Discovery research: The scientific challenge of finding new antibiotics. J. Antimicrob. Chemother. 2011, 66, 1941–1944. [Google Scholar] [CrossRef] [PubMed]
  8. Rex, J.H. ND4BB: Addressing the antimicrobial resistance crisis. Nat. Rev. Microbiol. 2014, 12, 231–232. [Google Scholar] [CrossRef]
  9. Spanò, V.; Parrino, B.; Carbone, A.; Montalbano, A.; Salvador, A.; Brun, P.; Vedaldi, D.; Diana, P.; Cirrincione, G.; Barraja, P. Pyrazolo[3,4-h]quinolines promising photosensitizing agents in the treatment of cancer. Eur. J. Med. Chem. 2015, 102, 334–351. [Google Scholar] [CrossRef] [PubMed]
  10. Faty, R.M.; Rashed, M.S.; Youssef, M.M. Microwave-assisted synthesis and antimicrobial evaluation of novel spiroisoquinoline and spiropyrido[4,3-d]pyrimidine derivatives. Molecules 2015, 20, 1842–1859. [Google Scholar] [CrossRef] [PubMed]
  11. Eda, M.; Kuroda, T.; Kaneko, S.; Aoki, Y.; Yamashita, M.; Okumura, C.; Ikeda, Y.; Ohbora, T.; Sakaue, M.; Koyama, N.; et al. Synthesis and Biological Evaluation of Cyclopentaquinoline Derivatives as Nonsteroidal Glucocorticoid Receptor Antagonists. J. Med. Chem. 2015, 58, 4918–4926. [Google Scholar] [CrossRef] [PubMed]
  12. Andriole, V.T. The quinolones: Past, present, and future. Clin. Infect. Dis. 2005, 41, S113–S119. [Google Scholar] [CrossRef] [PubMed]
  13. Velu, A.B.; Chen, G.W.; Hsieh, P.T.; Horng, J.T.; Hsu, J.T.; Hsieh, H.P.; Chen, T.C.; Weng, K.F.; Shih, S.R. BPR-3P0128 inhibits RNA-dependent RNA polymerase elongation and VPg uridylylation activities of Enterovirus71. Antivir. Res. 2014, 112, 18–25. [Google Scholar] [CrossRef] [PubMed]
  14. Zarghi, A.; Ghodsi, R. Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. 2010, 18, 5855–5860. [Google Scholar] [CrossRef] [PubMed]
  15. Garudachari, B.; Satyanarayana, M.N.; Thippeswamy, B.; Shivakumar, C.K.; Shivananda, K.N.; Hegde, G.; Isloor, A.M. Synthesis, characterization and antimicrobial studies of some new quinoline incorporated benzimidazole derivatives. Eur. J. Med. Chem. 2012, 54, 900–906. [Google Scholar] [CrossRef] [PubMed]
  16. Huang, A.; Moretto, A.; Janz, K.; Lowe, M.; Bedard, P.W.; Tam, S.; Di, L.; Clerin, V.; Sushkova, N.; Tchernychev, B.; et al. Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury. J. Med. Chem. 2010, 53, 6003–6017. [Google Scholar] [CrossRef] [PubMed]
  17. Kishibayashi, N.; Miwa, Y.; Hayashi, H.; Ishii, A.; Ichikawa, S.; Nonaka, H.; Yokoyama, T.; Suzuki, F. 5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome. J. Med. Chem. 1993, 36, 3286–3292. [Google Scholar] [CrossRef] [PubMed]
  18. Vendruscolo, L.F.; Takahashi, R.N.; Brüske, G.R.; Ramos, A. Evaluation of the anxiolytic-like effect of NKP608, a NK1-receptor antagonist, in two rat strains that differ inanxiety-related behaviors. Psychopharmacology 2003, 170, 287–293. [Google Scholar] [CrossRef] [PubMed]
  19. Boa, A.N.; Canavan, S.P.; Hirst, P.R.; Ramsey, C.; Stead, A.M.; McConkey, G.A. Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase. Bioorg. Med. Chem. 2005, 13, 1945–1967. [Google Scholar] [CrossRef] [PubMed]
  20. Dinakaran, M.; Senthilkumar, P.; Yogeeswari, P.; China, A.; Nagaraja, V.; Sriram, D. Synthesis, antimycobacterial activities and phototoxic evaluation of 5H-thiazolo[3,2-a]-quinoline-4-carboxylicacid derivatives. Med. Chem. 2008, 4, 482–491. [Google Scholar] [CrossRef] [PubMed]
  21. Strigacova, J.; Hudecova, D.; Varecka, L.; Lasikova, A.; Vegh, D. Some biological properties of new quinoline-4-carboxylic acid and quinoline-4-carboxamide derivatives. Folia Microbiol. 2000, 45, 305–309. [Google Scholar] [CrossRef]
  22. Metwally, K.A.; Abdel-Aziz, L.M.; Lashine el, S.M.; Husseiny, M.I.; Badawy, R.H. Hydrazones of 2-arylquinoline-4-carboxylic acid hydrazides: Synthesis and preliminary evaluation as antimicrobial agents. Bioorg. Med. Chem. 2006, 14, 8675–8682. [Google Scholar] [CrossRef] [PubMed]
  23. Wadher, S.J.; Karande, N.A.; Borkar, D.S.; Yeole, P.G. Synthesis and biological evaluation of Schiff bases of Cinchophen as antimicrobial agents. Int. J. ChemTech Res. 2009, 1, 1297–1302. [Google Scholar]
  24. Saeed, A.E.M.; Elhadi, S.A. Synthesis of some 2-aryl- and 2,3-diaryl-quinolin-4-carboxylic acid derivatives. Synth. Commun. 2011, 41, 1435–1443. [Google Scholar] [CrossRef]
  25. Muscia, G.C.; Carnevale, J.P.; Bollini, M.; Asís, S.E. Microwave-assisted Döbner Synthesis of 2-Phenylquinoline-4-carboxylic Acids and their Antiparasitic Activities. J. Heterocycl. Chem. 2008, 45, 611–614. [Google Scholar] [CrossRef]
  26. Bhatt, H.G.; Agrawal, Y.K. Microwave-irradiated synthesis and antimicrobial activity of 2-phenyl-7-substitutedalkyl/arylaminoquinoline-4-carboxylic acid derivatives. Med. Chem. Res. 2010, 19, 392–402. [Google Scholar] [CrossRef]
  27. Baragaña, B.; Hallyburton, I.; Lee, M.C.; Norcross, N.R.; Grimaldi, R. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature 2015, 522, 315–320. [Google Scholar] [CrossRef] [PubMed]
  28. Kumar, R.; Kumar, A.; Jain, S.; Kaushik, D. (2011) Synthesis, antibacterial evaluation and QSAR studies of 7-[4-(5-aryl-1,3,4-oxadiazole-2-yl)piperazinyl] quinolone derivatives. Eur. J. Med. Chem. 2011, 46, 3543–3550. [Google Scholar] [CrossRef] [PubMed]
  29. Abuo-Rahma, G.D.; Sarhan, H.A.; Gad, G.F. Design, synthesis, antibacterial activity and physicochemical parameters of novel N-4-piperazinyl derivatives of norfloxacin. Bioorg. Med. Chem. 2009, 17, 3879–3886. [Google Scholar] [CrossRef] [PubMed]
  30. Zarghi, A.; Ghodsi, R.; Azizi, E.; Daraie, B.; Hedayati, M.; Dadrass, O.G. Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. 2009, 17, 5312–5317. [Google Scholar] [CrossRef] [PubMed]
  31. Alexandre, V.I.; Alexander, V.K.; Vladimir, V.K.; Volodymir, M.K.; Caroline, T.W. A new insight into the Pfitzinger reaction. A facile synthesis of 6-sulfamoylquinoline-4-carboxylic acids. Tetrahedron Lett. 2004, 45, 5473–5476. [Google Scholar]
  32. Duvelleroy, D.; Perrio, C.; Parisel, O.; Lasne, M.C. Rapid synthesis of quinoline-4-carboxylic acid derivatives from arylimines and 2-substituted acrylates or acrylamides under indium(III) chloride and microwave activations. Scope and limitations of the reaction. Org. Biomol. Chem. 2005, 3, 3794–3804. [Google Scholar] [CrossRef] [PubMed]
  33. Tu, S.; Zhu, X.; Zhang, J.; Xu, J.; Zhang, Y.; Wang, Q.; Jia, R.; Jiang, B.; Zhang, J.; Yao, C. New potential biologically active compounds: Design and an efficient synthesis of N-substituted-4-aryl-4,6,7,8-tetrahydroquinoline-2,5(1H,3H)-diones under microwave irradiation. Bioorg. Med. Chem. Lett. 2006, 16, 2925–2928. [Google Scholar] [CrossRef] [PubMed]
  34. Li, Z.; Tan, J.H.; He, J.H.; Long, Y.; Ou, T.M.; Li, D.; Gu, L.Q.; Huang, Z.S. Disubstituted quinazoline derivatives as new type of highly selective ligands for telomeric G-quadruplex DNA. Eur. J. Med. Chem. 2012, 47, 299–311. [Google Scholar] [CrossRef] [PubMed]
  35. Arthington-Skaggs, B.A.; Motley, M.; Warnock, D.W.; Morrison, C.J. Comparative evaluation of PASCO and national committee for clinical laboratory standards M27-A broth microdilution methods for antifungal drug susceptibility testing of yeasts. J. Clin. Microbiol. 2000, 38, 2254–2260. [Google Scholar] [PubMed]
  36. Cong, N.T.; Nhan, H.T.; Van Hung, L.; Thang, T.D.; Kuo, P.C. Synthesis and antibacterial activity of analogs of 5-arylidene-3-(4-methylcoumarin-7-yloxyacetylamino)-2-thioxo-1,3-thiazoli-din-4-one. Molecules 2014, 19, 13577–13586. [Google Scholar] [CrossRef] [PubMed]
  37. Mickevičienė, K.; Baranauskaitė, R.; Kantminienė, K.; Stasevych, M.; Komarovska-Porokhnyavets, O.; Novikov, V. Synthesis and antimicrobial activity of N-substituted-β- amino acid derivatives containing 2-hydroxyphenyl, benzo[b]phenoxazine and quinoxaline moieties. Molecules 2015, 20, 3170–3189. [Google Scholar] [CrossRef] [PubMed]
  38. Jordão, A.K.; Novais, J.; Leal, B.; Escobar, A.C.; dos Santos, H.M., Jr.; Castro, H.C.; Ferreira, V.F. Synthesis using microwave irradiation and antibacterial evaluation of new N,O-acetals and N,S-acetals derived from 2-amino-1,4-naphthoquinones. Eur. J. Med. Chem. 2013, 63, 196–201. [Google Scholar] [CrossRef] [PubMed]
  39. Lei, X.; Li, J.; Liu, B.; Zhang, N.; Liu, H. Separation and Identification of Four New Compounds with Antibacterial Activity from Portulaca oleracea L. Molecules 2015, 20, 16375–16387. [Google Scholar] [CrossRef] [PubMed]
  40. Geng, Z.Z.; Zhang, J.J.; Lin, J.; Huang, M.Y.; An, L.K.; Zhang, H.B.; Sun, P.H.; Ye, W.C.; Chen, W.M. Novel cajaninstilbene acid derivatives as antibacterial agents. Eur. J. Med. Chem. 2015, 100, 235–245. [Google Scholar] [CrossRef] [PubMed]
  41. Suresh, N.; Nagesh, H.N.; Renuka, J.; Rajput, V.; Sharma, R.; Khan, I.A.; Kondapalli Venkata Gowri, C.S. Synthesis and evaluation of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-(2-(4-substituted-piperazin-1-yl)acetyl)piperazin-1-yl)quinoline-3-carboxylic acid derivatives as anti-tubercular and antibacterial agents. Eur. J. Med. Chem. 2014, 71, 324–332. [Google Scholar] [CrossRef] [PubMed]
  • Sample Availability: Samples of the compounds 5a1–5a7, 5b1–5b6 are available from the authors.
Molecules 21 00340 g001 550
Figure 1. The structures of 2-aryl-quinoline-4-carboxylic acid derivatives with antimicrobial activities.
Figure 1. The structures of 2-aryl-quinoline-4-carboxylic acid derivatives with antimicrobial activities.
Molecules 21 00340 g001
Molecules 21 00340 g002 550
Scheme 1. Synthetic route of 2-phenyl-quinoline-4-carboxylic acid derivatives.
Scheme 1. Synthetic route of 2-phenyl-quinoline-4-carboxylic acid derivatives.
Molecules 21 00340 g002
Table
Table 1. Antibacterial activities of the synthesized compounds determined by the agar diffusion method.
Table 1. Antibacterial activities of the synthesized compounds determined by the agar diffusion method.
Zone of Inhibition in mm (Mean ± SD) n = 3
CompoundLogPB. subtilisS. aureusE. coliP. aeruginosaMRSA
Concentration (μg/mL) 5010050100501005010050100
5a10.321 ± 0.22 ± 0.53 ± 0.25 ± 0.42 ± 0.12 ± 0.51 ± 0.11 ± 0.23 ± 0.23 ± 0.4
5a21.692 ± 0.32 ± 0.215 ± 0.517 ± 0.14 ± 0.25 ± 0.52 ± 0.53 ± 0.43 ± 0.16 ± 0.3
5a31.0510 ± 0.111 ± 0.514 ± 0.216 ± 0.53 ± 0.23 ± 0.42 ± 0.22 ± 0.54 ± 0.35 ± 0.4
5a42.2612 ± 0.313 ± 0.218 ± 0.220 ± 0.12 ± 0.53 ± 0.2005 ± 0.56 ± 0.2
5a50.606 ± 0.27 ± 0.47 ± 0.18 ± 0.5003 ± 0.15 ± 0.12 ± 0.43 ± 0.5
5a60.87000010 ± 0.213 ± 0.11 ± 0.22 ± 0.400
5a71.94001 ± 0.52 ± 0.112 ± 0.514 ± 0.10000
5b10.721 ± 0.11 ± 0.22 ± 0.13 ± 0.5000000
5b21.753 ± 0.34 ± 0.24 ± 0.27 ± 0.12 ± 0.33 ± 0.40000
5b31.203 ± 0.53 ± 0.14 ± 0.16 ± 0.34 ± 0.26 ± 0.41 ± 0.22 ± 0.100
5b42.3210 ± 0.112 ± 0.58 ± 0.510 ± 0.13 ± 0.35 ± 0.1005 ± 0.27 ± 0.4
5b51.001 ± 0.23 ± 0.34 ± 0.55 ± 0.4000000
5b60000010 ± 0.511 ± 0.23 ± 0.14 ± 0.300
13.542 ± 0.53 ± 0.13 ± 0.55 ± 0.13 ± 0.14 ± 0.31 ± 0.42 ± 0.200
Control a 0000000000
Ampicillin 32 ± 0.3- b25 + 0.4-15 ± 0.4-12 ± 0.2-1 ± 0.41 ± 0.1
Gentamycin 10 ± 0.5-14 ± 0.3-17 ± 0.1-20 ± 0.4-00
a Dimethyl sulfoxide; b not determined.
Table
Table 2. The minimum inhibitory concentration (MIC) values of the synthesized compounds against bacteria.
Table 2. The minimum inhibitory concentration (MIC) values of the synthesized compounds against bacteria.
CompoundMIC (μg/ mL)
B. subtilisS. aureusE. coliP. aeruginosaMRSA
5a1>512>512>512>512>512
5a2>512128512>512512
5a3256128>512>512>512
5a425664>512-a512
5a5512256-512>512
5a6--256>512-
5a7->512128--
5b1>512>512---
5b2>512512>512--
5b3>512512512>512-
5b4256128>512-512
5b5>512>512---
5b6--256>512-
1>512512>512>512-
Ampicillin16166464512
Gentamycin6416168-
a Not determined.
Table
Table 3. IC50 (μg/mL) values of the compounds against mouse macrophage cell lines (RAW 264.7 a).
Table 3. IC50 (μg/mL) values of the compounds against mouse macrophage cell lines (RAW 264.7 a).
CompoundIC50 b (μg/mL)
5a498.24 ± 0.65
5a756.83 ± 0.32
Ampicillin107.58± 0.47
Gentamycin42.19 ± 0.19
a RAW 264.7 monolayers were used as an in vitro model of cervicovaginal epithelium for testing the cytotoxicity of the new compounds; b IC50 is defined as the concentration at which 50% of growth is inhibited.

Share and Cite

MDPI and ACS Style

Wang, X.; Xie, X.; Cai, Y.; Yang, X.; Li, J.; Li, Y.; Chen, W.; He, M. Design, Synthesis and Antibacterial Evaluation of Some New 2-Phenyl-quinoline-4-carboxylic Acid Derivatives. Molecules 2016, 21, 340. https://doi.org/10.3390/molecules21030340

AMA Style

Wang X, Xie X, Cai Y, Yang X, Li J, Li Y, Chen W, He M. Design, Synthesis and Antibacterial Evaluation of Some New 2-Phenyl-quinoline-4-carboxylic Acid Derivatives. Molecules. 2016; 21(3):340. https://doi.org/10.3390/molecules21030340

Chicago/Turabian Style

Wang, Xiaoqin, Xiaoyang Xie, Yuanhong Cai, Xiaolan Yang, Jiayu Li, Yinghan Li, Wenna Chen, and Minghua He. 2016. "Design, Synthesis and Antibacterial Evaluation of Some New 2-Phenyl-quinoline-4-carboxylic Acid Derivatives" Molecules 21, no. 3: 340. https://doi.org/10.3390/molecules21030340

Article Metrics

Back to TopTop